Novel etiological and therapeutic strategies for neurodiseases: RNA editing enzyme abnormality in sporadic amyotrophic lateral sclerosis

Journal of Pharmacological Sciences

Volumn 113, Issue 1, 2010, Pages 9-13

  Hideyama, Takuto ^a   Yamashita, Takenari ^a   Nishimoto, Yoshinori ^b   Suzuki, Takeshi ^b   Kwak, Shin ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Amyotrophic lateral sclerosis (ALS); Cytoplasmic fragile X mental retardation protein interacting protein 2 (CYFIP2); GluR2 Q R; Neurodisease; RNA editing; amino 3 hydroxy 5 methyl 4 isoxazolepropionate (AMPA) receptor

Indexed keywords

ADAR2 PROTEIN; ADENOSINE DEAMINASE; AMPA RECEPTOR; CYTOPLASMIC FRAGILE X MENTAL RETARDATION PROTEIN INTERACTING PROTEIN 2; FRAGILE X MENTAL RETARDATION PROTEIN; MESSENGER RNA; RNA; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; EPILEPSY; GENE MUTATION; HUMAN; MOTONEURON; NERVE CELL NECROSIS; NEUROLOGIC DISEASE; NONHUMAN; REVIEW; RNA EDITING; RNA INTERFERENCE;

EID: 77953517354     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09R21FM     Document Type: Review

References (38)

1. Jackson M, Al-Chalabi A, Enayat ZE, Chioza B, Leigh PN, Morrison KE. Copper/zinc superoxide dismutase 1 and sporadic amyotrophic lateral sclerosis: analysis of 155 cases and identification of a novel insertion mutation. Ann Neurol. 1997;42:803-807.
2. Rothstein J, Tsai G, Kuncl R, Clawson L, Cornblath D, Drachman D, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol. 1990;28:18-25.
3. Durlach J, Bac P, Durlach V, Durlach A, Bara M, Guiet-Bara A. Are age-related neurodegenerative diseases linked with various types of magnesium depletion? Magnes Res. 1997;10:339-353.
4. Hoffman PM, Robbins DS, Oldstone MB, Gibbs CJ Jr, Gajdusek DC. Humoral immunity in Guamanians with amyotrophic lateral sclerosis and parkinsonism-dementia. Ann Neurol. 1981;10:193-196.
5. Moulignier A, Moulonguet A, Pialoux G, Rozenbaum W. Reversible ALS-like disorder in HIV infection. Neurology. 2001;57:995-1001.
6. Rao AV, Balachandran B. Role of oxidative stress and antioxidants in neurodegenerative diseases. Nutr Neurosci. 2002;5:291-309.
7. Allaoua H, Chaudieu I, Krieger C, Boksa P, Privat A, Quirion R. Alterations in spinal cord excitatory amino acid receptors in amyotrophic lateral sclerosis patients. Brain Res. 1992;579:169-172.
8. Vandenberghe W, Robberecht W, Brorson J. AMPA receptor calcium permeability, GluR2 expression, and selective motoneuron vulnerability. J Neurosci. 2000;20:123-132.
9. Rothstein JD, Kuncl RW. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem. 1995;65:643-651.
10. Kwak S, Weiss JH. Calcium-permeable AMPA channels in neurodegenerative disease and ischemia. Curr Opin Neurobiol. 2006; 16:281-287.
11. Kawahara Y, Kwak S. Excitotoxicity and ALS: what is unique about the AMPA receptors expressed on spinal motor neurons? Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6: 131-144.
12. Takuma H, Kwak S, Yoshizawa T, Kanazawa I. Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol. 1999;46:806-815.
13. Kawahara Y, Ito K, Sun H, Aizawa H, Kanazawa I, Kwak S. Glutamate receptors: RNA editing and death of motor neurons. Nature. 2004;427:801.
14. Kwak S, Kawahara Y. Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis. J Mol Med. 2005;83: 110-120.
15. Higuchi M, Maas S, Single F, Hartner J, Rozov A, Burnashev N, et al. Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature. 2000;406:78-81.
16. Burnashev N, Monyer H, Seeburg P, Sakmann B. Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit. Neuron. 1992;8:189-198.
17. Köhler M, Burnashev N, Sakmann B, Seeburg P. Determinants of Ca 2+ permeability in both TM1 and TM2 of high affinity kainate receptor channels: diversity by RNA editing. Neuron. 1993; 10:491-500.
18. Paschen W, Djuricic B. Extent of RNA editing of glutamate receptor subunit GluR5 in different brain regions of the rat. Cell Mol Neurobiol. 1994;14:259-270.
19. Paschen W, Schmitt J, Dux E, Djuricic B. Temporal analysis of the upregulation of GluR5 mRNA editing with age: regional evaluation. Brain Res Dev Brain Res. 1995;86:359-363.
20. Paschen W, Djuricic B. Regional differences in the extent of RNA editing of the glutamate receptor subunits GluR2 and GluR6 in rat brain. J Neurosci Methods. 1995;56:21-29.
21. Schmitt J, Dux E. Gissel C, Paschen W. Regional analysis of developmental changes in the extent of GluR6 mRNA editing in rat brain. Brain Res DevelopBrain Res. 1996;91:153-157.
22. Bernard A, Ferhat L, Dessi F, Charton G, Represa A, Ben-Ari Y, et al. Q/R editing of the rat GluR5 and GluR6 kainate receptors in vivo and in vitro: evidence for independent developmental, pathological and cellular regulation. Eur J Neurosci. 1999;11:604-616.
23. Kawahara Y, Ito K, Sun H, Kanazawa I, Kwak S. Low editing efficiency of GluR2 mRNA is associated with a low relative abundance of ADAR2 mRNA in white matter of normal human brain. Eur J Neurosci. 2003;18:23-33.
24. Barbon A, Vallini I, La Via L, Marchina E, Barlati S. Glutamate receptor RNA editing: a molecular analysis of GluR2, GluR5 and GluR6 in human brain tissues and in NT2 cells following in vitro neural differentiation. Brain Res Mol Brain Res. 2003;117:168-178.
25. Kortenbruck G, Berger E, Speckmann EJ, Musshoff U. RNA editing at the Q/R site for the glutamate receptor subunits GLUR2, GLUR5, and GLUR6 in hippocampus and temporal cortex from epileptic patients. Neurobiol Dis. 2001;8:459-468.
26. Englander MT, Dulawa SC, Bhansali P, Schmauss C. How stress and fluoxetine modulate serotonin 2C receptor pre-mRNA editing. J Neurosci 2005;25:648-651.
27. Iwamoto K, Bundo M, Kato T. Estimating RNA editing efficiency of five editing sites in the serotonin 2C receptor by pyrosequencing. Rna 2005;11:1596-1603.
28. Takuma H, Kwak S, Yoshizawa T, Kanazawa I. Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol. 1999;46:806-815.
29. Kwak S, Takuma H, Kanazawa I. Molecular mechanism and therapeutics of amyotrophic lateral sclerosis. San Diego, CA: Elsevier Science B.V.; 2001.
30. Li JB, Levanon EY, Yoon JK, Aach J, Xie B, Leproust E, et al. Genome-wide identification of human RNA editing sites by parallel DNA capturing and sequencing. Science. 2009;324:1210-1213.
31. Melcher T, Maas S, Herb A, Sprengel R, Seeburg P, Higuchi M. A mammalian RNA editing enzyme. Nature. 1996;379:460-464.
32. Wang Q, Khillan J, Gadue P, Nishikura K. Requirement of the RNA editing deaminase ADAR1 gene for embryonic erythropoiesis Science. 2000;290:1765-1768.
33. Melcher T, Maas S, Herb A, Sprengel R, Higuchi M, Seeburg PH. RED2, a brain-specific member of the RNA-specific adenosine deaminase family. J Biol Chem. 1996;271:31795-31798.
34. Chen CX, Cho DS, Wang Q, Lai F, Carter KC, Nishikura K. A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single-and double-stranded RNA binding domains. RNA. 2000;6:755-767.
35. Levanon EY, Hallegger M, Kinar Y, Shemesh R, Djinovic-Carugo K, Rechavi G, et al. Evolutionarily conserved human targets of adenosine to inosine RNA editing. Nucleic Acids Res. 2005;33: 1162-1168.
36. Kwak S, Nishimoto Y, Yamashita T. Newly identified ADARmediated A-to-I editing positions as a tool for ALS research. RNA Biol. 2008;5:193-197.
37. Nishimoto Y, Yamashita T, Hideyama T, Tsuji S, Suzuki N, Kwak S. Determination of editors at the novel A-to-I editing positions. Neurosci Res. 2008;61:201-206.
38. Riedmann EM, Schopoff S, Hartner JC, Jantsch MF. Specificity of ADAR-mediated RNA editing in newly identified targets. RNA. 2008;14:1110-1118.